Phathom Pharmaceuticals, Inc.
PHAT
$3.31
$0.165.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -26.68% | 13.00% | 6.42% | -10.37% | -4.12% |
| Total Depreciation and Amortization | -8.29% | 1.05% | -3.05% | -7.94% | 15.68% |
| Total Amortization of Deferred Charges | 10.65% | 81.79% | -53.43% | 56.75% | -16.25% |
| Total Other Non-Cash Items | -9.28% | -4.35% | -1.61% | 1.22% | -41.29% |
| Change in Net Operating Assets | 1.35% | -752.42% | 321.25% | 91.08% | -1,138.61% |
| Cash from Operations | -33.84% | 0.18% | 10.11% | -2.46% | -57.59% |
| Capital Expenditure | -260.00% | 88.64% | 4.35% | -15.00% | 91.58% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -260.00% | 88.64% | 4.35% | -15.00% | 91.58% |
| Total Debt Issued | -- | -- | -100.00% | 150.00% | -95.33% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -98.94% | 581,123.81% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -78.66% | 392.74% | 150.21% | -95.33% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -127.04% | -164.02% | 227.05% | 22.25% | -135.27% |